Compare DexCom, Inc. (DXCM) vs Freeport-McMoRan Inc (FCX) Price & Performance

DXCM trades at $91.48, up 2.18% today, near its 52-week high. The stock shows strong bullish momentum with consistent earnings beats, including Q2 2026 EPS of $0.70 versus $0.61 expected. Revenue growth accelerated to $4.66 billion in 2025, with net income margins improving to 17.93%. Technical indicators signal bullish trends, supported by moving averages, while RSI levels indicate potential overbought conditions. Recent news highlights raised 2026 guidance driven by G7 system adoption and international expansion.

Outlook remains positive due to robust fundamentals and analyst consensus, but risks include premium valuation and competitive pressures. The stock offers growth potential from expanding CGM market share, though investors should monitor margin sustainability and litigation concerns. With 80% buy ratings and a consensus price target of $88.65, near-term upside may be limited, but long-term growth drivers are intact.

FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.

The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.